Gout

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.

Monosodium urate deposits significantly increased the risk of major cardiovascular events in patients with gout and hyperuricemia.

Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.

The incidence of gout was 2.9 per 1000 patient-years, which dropped by 30% at the beginning of the COVID-19 pandemic.

Strategies designed to promote medication adherence were found in only 1 out of 3 websites.

An observational study in the UK investigated the risk of adverse events related to colchicine prophylaxis after receiving allopurinol for gout.

After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.

A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.

NSAID use decreased the odds of a cardiovascular event by 12% in patients with gout.

Patient-led urate monitoring supports adherence to urate-lowering therapy and helps attain target concentrations among individuals with gout.

Alkaline water significantly reduced VAS pain scores among patients with gout.

For those with a family history of gout, the proportion of grade ≥ 2 left ventricular diastolic insufficiency was markedly higher compared with patients without family history.

Patients with gout who had poor health literacy were more likely to experience ≥ 2 flares within the previous 12 months.

Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.

A meta-analysis found febuxostat was linked to a greater risk for acute coronary syndrome and atrial fibrillation than allopurinol among Asian patients with and without gout.

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.

Results showed co-administration of methotrexate with pegloticase led to similar rates of urate-lowering response and adverse events in patients with and without CKD.

A comparison of the urate-lowering therapies shows discrepancies in short- and long-term use outcomes.

From 1990 to 2019, the prevalence, incidence, and disability-adjusted life years of gout worldwide increased by 22.4%, 18%, and 22.2%, respectively.

Test your knowledge of the ACR's guideline for the management of gout with this quiz!

Findings provide insights into the current state of healthcare utilization for patients with gout living in South Korea.

Patients with gout and negative DECTs for monosodium urate crystal deposition exhibited milder disease and a lower comorbidity burden.

Among patients aged 40 – 49 years, asymptomatic hyperuricemia was linked to incident arthritis.

Often considered a cause of symptom onset in musculoskeletal conditions, a new study found that weather factors do not appear to be a risk factor for pain.

These data contribute to existing research into links observed between rheumatic diseases such as gout and cardiovascular disease among Indigenous North American populations.

Interactions with alcohol consumption were identified at ADH1B and MLXIPL for association with serum urate level and at ADH1B for association with hyperuricemia and gout

A new study found the odds of gout were 2.65 times greater in patients with OSA than in patients without OSA.

A recent study points to a link between bisphenol exposure and elevated uric acid levels, with implications for gout risk, especially in women.

A new study found people with depression are associated with an increased risk of gout. However, not many people with both depression and gout sought out treatment (0.2%).

Urate-lowering therapy and dosing regimen impact the risk of gout flares, with greater fixed dosing linked to a greater risk of flares and prophylaxis associated with reductions in flare risk.